BIT Capital GmbH Has $5.05 Million Holdings in Arvinas, Inc. (NASDAQ:ARVN)

BIT Capital GmbH raised its holdings in shares of Arvinas, Inc. (NASDAQ:ARVN - Free Report) by 291.7% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 263,527 shares of the company's stock after buying an additional 196,246 shares during the period. BIT Capital GmbH owned about 0.38% of Arvinas worth $5,052,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. JPMorgan Chase & Co. raised its holdings in Arvinas by 18.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,329,303 shares of the company's stock worth $57,371,000 after buying an additional 367,343 shares during the period. Baker BROS. Advisors LP acquired a new stake in shares of Arvinas during the third quarter valued at approximately $9,989,000. SG Americas Securities LLC lifted its position in shares of Arvinas by 228.8% in the 4th quarter. SG Americas Securities LLC now owns 32,424 shares of the company's stock valued at $622,000 after acquiring an additional 22,564 shares in the last quarter. Wasatch Advisors LP boosted its stake in Arvinas by 58.3% in the 3rd quarter. Wasatch Advisors LP now owns 435,943 shares of the company's stock worth $10,737,000 after purchasing an additional 160,510 shares during the period. Finally, Barclays PLC raised its stake in Arvinas by 198.9% during the 3rd quarter. Barclays PLC now owns 121,699 shares of the company's stock valued at $2,998,000 after purchasing an additional 80,984 shares during the period. Institutional investors and hedge funds own 95.19% of the company's stock.

Insider Activity

In other Arvinas news, insider Ian Taylor sold 9,020 shares of the business's stock in a transaction dated Monday, February 24th. The stock was sold at an average price of $16.71, for a total transaction of $150,724.20. Following the completion of the sale, the insider now directly owns 159,121 shares of the company's stock, valued at approximately $2,658,911.91. The trade was a 5.36 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO John G. Houston sold 31,338 shares of the business's stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $16.72, for a total transaction of $523,971.36. Following the transaction, the chief executive officer now owns 1,157,480 shares of the company's stock, valued at approximately $19,353,065.60. This represents a 2.64 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,230 shares of company stock worth $769,402. 5.23% of the stock is owned by corporate insiders.

Arvinas Stock Down 6.7 %

NASDAQ:ARVN traded down $0.51 on Monday, reaching $7.09. The stock had a trading volume of 1,213,363 shares, compared to its average volume of 1,806,812. The company has a market capitalization of $487.25 million, a P/E ratio of -2.55 and a beta of 1.95. The stock has a fifty day moving average price of $15.27 and a 200-day moving average price of $20.64. Arvinas, Inc. has a 1-year low of $6.97 and a 1-year high of $41.34.

Arvinas (NASDAQ:ARVN - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, topping analysts' consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same quarter last year, the firm posted ($2.53) EPS. Sell-side analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ARVN has been the topic of several recent analyst reports. BTIG Research assumed coverage on Arvinas in a research report on Tuesday, December 10th. They set a "buy" rating and a $69.00 price target on the stock. Wells Fargo & Company set a $26.00 target price on Arvinas and gave the company an "overweight" rating in a report on Wednesday, March 12th. BMO Capital Markets set a $20.00 price objective on shares of Arvinas and gave the company an "outperform" rating in a research report on Wednesday, March 12th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a research note on Friday, February 7th. Finally, Barclays decreased their target price on shares of Arvinas from $48.00 to $32.00 and set an "overweight" rating for the company in a research note on Monday, February 3rd. Five investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Arvinas presently has an average rating of "Moderate Buy" and a consensus target price of $35.50.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.